Stay updated on Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedLocations were consolidated into one Locations section with individual state subsections (California, Massachusetts, Nevada, Ohio, Oklahoma, Pennsylvania). This update is part of revision v3.3.3.SummaryDifference0.6%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check38 days agoChange DetectedDeleted the generic government funding/operating status notice; the study content and eligibility criteria remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check60 days agoChange DetectedThe new screenshot shows only minor formatting and layout adjustments with no changes to core study details (title, conditions, eligibility criteria, locations, or results). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check81 days agoChange DetectedAdded an important government-operating-status notice and a new version tag v3.2.0; removed the old version tag v3.1.0.SummaryDifference2%

- Check88 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab Combo in FRα+ Ovarian Cancer Clinical Trial page.